Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype

Cancer Research

Volumn 69, Issue 3, 2009, Pages 836-844

  Almog, Nava ^a,b   Ma, Lili ^a   Raychowdhury, Raktima ^a   Schwager, Christian ^c   Erber, Ralf ^d   Short, Sarah ^b   Hlatky, Lynn ^a   Vajkoczy, Peter ^d   Huber, Peter E ^a,c   Folkman, Judah ^b   Abdollahi, Amir ^a,b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ANGIOSTATIN; ENDOTHELIAL CELL SPECIFIC MOLECULE 1; EPHRIN RECEPTOR A5; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE H2B; HISTONE H2BK; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEOGLYCAN; SOMATOMEDIN RECEPTOR; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TROPOMYOSIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DORMANCY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; LIPOSARCOMA; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTOR, EPHA5; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION, GENETIC; TROPOMYOSIN;

EID: 59149083473     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2590     Document Type: Article

References (34)

1. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787.
2. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237-43.
3. Naumov GN, Folkman J. Strategies to prolong the nonangiogenic dormant state of human cancer. In: Davis DW, Herbst RS, Abbruzzese JL, editors. Antiangiogenic cancer therapy. Boca Raton (FL): CRC Press; 2008. p. 3-21.
4. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46.
5. Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-76.
6. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
7. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7.
8. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-25.
9. Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E. Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. Adv Cancer Res 2007;97:189-202.
10. Udagawa T, Fernandez A, Achilles EG, Folkman J, D'Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002;16:1361-70.
11. Almog N, Henke V, Flores L, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006;20:947-9.
12. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins. J Cell Biol 2005;168:643-53.
13. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
14. Abdollahi A, Schwager C, Kleeff J, et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A 2007;104:12890-5.
15. Ernkvist M, Aase K, Ukomadu C, et al. p130-angiomotin associates to actin and controls endothelial cell shape. FEBS J 2006;273:2000-11.
16. Achilles EG, Fernandez A, Allred EN, et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst 2001;93:1075-81.
17. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152:1247-54.
18. Miescher GC, Taylor V, Olivieri G, Mindermann T, Schrock E, Steck AJ. Extensive splice variation and localization of the EHK-1 receptor tyrosine kinase in adult human brain and glial tumors. Brain Res Mol Brain Res 1997;46:17-24.
19. Bratt A, Wilson WJ, Troyanovsky B, et al. Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 2002;298:69-77.
20. Bratt A, Birot O, Sinha I, et al. Angiomotin regulates endothelial cell-cell junctions and cell motility. J Biol Chem 2005;280:34859-69.
21. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
22. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998;101:1055-63.
23. Yancopoulos GD, Klagsbrun M, Folkman J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998;93:661-4.
24. MacDonald NJ, Shivers WY, Narum DL, et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001;276:25190-6.
25. Donate F, McCrae K, Shaw DE, Mazar AP. Extracellular tropomyosin: a novel common pathway target for anti-angiogenic therapy. Curr Cancer Drug Targets 2004;4:543-53.
26. Mallery SR, Morse MA, Wilson RF, et al. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion. J Cell Biochem 2003;89:133-43.
27. Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through upregulation of a collagen prolyl hydroxylase. Science 2006;313:968-71.
28. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
29. Foulstone E, Prince S, Zaccheo O, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005;205:145-53.
30. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-64.
31. Spychala J. Tumor-promoting functions of adenosine. Pharmacol Ther 2000;87:161-73.
32. Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006;72:136-45.
33. Scherpereel A, Gentina T, Grigoriu B, et al. Overexpression of endocan induces tumor formation. Cancer Res 2003;63:6084-9.
34. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770-5.